Categories: NewsPharmaceutical

BBS-Bioactive Bone Substitutes Plc: Managers’ Transactions – Pekka Jalovaara

BBS-Bioactive Bone Substitutes Plc, Company Announcement, 31 August 2022 16.00 (CEST)

BBS Bioactive Bone Substitutes Oyj  – Managers’ Transactions

____________________________________________

Person subject to the notification requirement

Name: Jalovaara, Pekka

Position: Member of the Board/Deputy member

Issuer: BBS Bioactive Bone Substitutes Oyj

LEI: 743700BYSBP0PCR6N767

Notification type: INITIAL NOTIFICATION

Reference number: 743700BYSBP0PCR6N767_20220826100002_2

____________________________________________

Transaction date: 2022-05-23

Venue not applicable

Instrument type: FINANCIAL INSTRUMENT LINKED TO A SHARE OR A DEBT INSTRUMENT

ISIN: FI4000522818

Nature of the transaction: DISPOSAL

Transaction details

(1): Volume: 55,862 Unit price: 0.0121 EUR

Aggregated transactions

(1): Volume: 55,862 Volume weighted average price: 0.0121 EUR

____________________________________________

Transaction date: 2022-05-24

Venue not applicable

Instrument type: FINANCIAL INSTRUMENT LINKED TO A SHARE OR A DEBT INSTRUMENT

ISIN: FI4000522818

Nature of the transaction: DISPOSAL

Transaction details

(1): Volume: 165,492 Unit price: 0.0085 EUR

Aggregated transactions

(1): Volume: 165,492 Volume weighted average price: 0.0085 EUR

____________________________________________

Transaction date: 2022-05-25

Venue not applicable

Instrument type: FINANCIAL INSTRUMENT LINKED TO A SHARE OR A DEBT INSTRUMENT

ISIN: FI4000522818

Nature of the transaction: DISPOSAL

Transaction details

(1): Volume: 4,662 Unit price: 0.006 EUR

(2): Volume: 61,786 Unit price: 0.0043 EUR

Aggregated transactions

(2): Volume: 66,448 Volume weighted average price: 0.00442 EUR

____________________________________________

Transaction date: 2022-05-27

Venue not applicable

Instrument type: FINANCIAL INSTRUMENT LINKED TO A SHARE OR A DEBT INSTRUMENT

ISIN: FI4000522818

Nature of the transaction: DISPOSAL

Transaction details

(1): Volume: 142,848 Unit price: 0.0013 EUR

(2): Volume: 71,400 Unit price: 0.0013 EUR

(3): Volume: 17,850 Unit price: 0.0013 EUR

Aggregated transactions

(3): Volume: 232,098 Volume weighted average price: 0.0013 EUR

For more information:

Ilkka Kangasniemi, CEO,
tel. +35840 7080307, e-mail: ilkka.kangasniemi@bbs-artebone.fi

Liisa Hukka, CFO,
tel. +35840 0611038, e-mail: liisa.hukka@bbs-artebone.fi

Certified Advisor:
Nordic Certified Adviser AB, tel. +46 70 551 67 29, info@certifiedadviser.se

BBS in brief

BBS-Bioactive Bone Substitutes is a health technology company that started operations in 2003. We have developed a new product for the treatment of severe bone fractures and lumber problems. Our goal is to provide a new generation of medical products for the treatment of bone damage in orthopaedic surgery. In the pharmaceutical sector, development and research requires perseverance and courage to develop new things. We have evidence of this for over 20 years. Our activities are characterised by top expertise, innovation and employees who are enthusiastic and committed to their work. The ARTEBONE ® in the final stages of product development, and we are looking for a CE marking that enables commercialisation in the EU. We are a company in Oulu with a pharmaceutical factory permit in Reisjärvi.

BBS-Bioactive Bone Substitutes Oyj:n shares have been listed in Nasdaq First North Growth Market Finland and Nasdaq First North Growth Market Sweden.

More information: www.bbs-artebone.fi

Staff

Recent Posts

Phio Pharmaceuticals Announces Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Marlborough, Massachusetts--(Newsfile Corp. - December 23, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical-stage…

46 minutes ago

ILiAD Biotechnologies Announces the Passing of Chief Operating Officer Ken Solovay

WESTON, Fla.--(BUSINESS WIRE)--ILiAD Biotechnologies, LLC (ILiAD), a clinical stage biotech company developing the world’s most…

3 hours ago

ILiAD Biotechnologies Announces the Passing of Chief Operating Officer Ken Solovay

WESTON, Fla.--(BUSINESS WIRE)--ILiAD Biotechnologies, LLC (ILiAD), a clinical stage biotech company developing the world’s most…

3 hours ago

Hallmark Adds Senior Executives to Enhance Customer Success and Strategic Partnerships

New leadership roles highlight Hallmark’s unique vendor-neutral approach to helping health systems build flexible, efficient,…

3 hours ago

CARESYNTAX ANNOUNCES 2024 HIGHLIGHTS

 Company Celebrates Continued Worldwide Progress Toward Data-Driven Surgery SAN FRANCISCO and BERLIN, Dec. 23, 2024…

3 hours ago

Medit Launches a Mobile App, MEDIT M, to Revolutionize Digital Dental Workflows

SEOUL, South Korea, Dec. 23, 2024 /PRNewswire/ -- Medit has launched a mobile app, MEDIT…

3 hours ago